Skip to main content

Bard Hernia Mesh Trial Rescheduled To October 16, 2023

Bard Hernia Mesh Trial Rescheduled To October 16, 2023

Bard Hernia Mesh Trial Rescheduled To October 16, 2023

Introduction

The third bellwether trial concerning accusations that the Bard PerFix Plug is defectively built and caused unpleasant problems following hernia surgery has been rescheduled to begin on October 16, 2023, by the United States District Court presiding over all Bard hernia mesh litigation.

The case was scheduled to begin in May 2023, as the third in a series of early trial dates meant to assist the parties judge how jurors are likely to respond to specific evidence and testimony that would be duplicated across more than 18,000 claims filed against C.R. Bard in a federal MDL (multidistrict litigation).

The judge has already presided over two MDL bellwether trials, which ended with mixed results. The first case went before a jury in August 2021, resulting in a defense verdict for Bard. That trial was followed by a second bellwether case that went before a jury in April 2022, resulting in a $255,000 verdict.

In August 2022, a state court lawsuit in Rhode Island resulted in a $4.8 million verdict over Bard hernia mesh problems, which sent a strong signal to the manufacturer about the extent of liability it may face in certain cases, as each lawsuit goes before a jury.

Each hernia mesh complaint makes similar claims, claiming that people had difficulties with various polypropylene products offered in recent years, such as the Bard PerFix Plug, Bard Ventralight, Bard Ventralex, Bard 3DMax, and other similar systems.

Because the charges raise comparable factual and legal issues, the lawsuit has been centralized and consolidated before the U.S. District Court since August 2018, for coordinated discovery and pretrial procedures. Yet, as fresh hernia mesh claims are filed and the devices continue to fail, the size of the MDL grows.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Study Finds Toxic Metals in E-Cigs and U-Cigs Vapors

Categories: E-Cigarette: JUUL

As health concerns about e-cigarette use escalate, emerging research suggests that a newer class of vaping products—ultrasonic cigarettes or u-cigarettes—may pose even greater risks.

A study published in Environmental Health Perspectives in…

Appeals Court Upholds $611M Roundup Verdict

Categories: Roundup

A Missouri appeals court has upheld a massive Roundup verdict originally totaling $1.5 billion, but significantly reduced the final amount Bayer and its Monsanto unit must pay to $611 million.

The case involved three plaintiffs from New…

Valsartan “Wave 2” Bellwether Trial Schedule Set by Court

Categories: Valsartan

As the first Valsartan bellwether trial approaches in September 2025, the federal judge overseeing the multidistrict litigation (MDL) is preparing a second set of trials.

This move comes in anticipation of the possibility that parties may…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!